Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zymeworks (ZYME) Shares Outstanding (Weighted Average) (2021 - 2025)

Zymeworks' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $75.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 0.58% to $75.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $75.4 million, a 0.58% decrease, with the full-year FY2025 number at $75.4 million, down 0.58% from a year prior.
  • Shares Outstanding (Weighted Average) hit $75.4 million in Q4 2025 for Zymeworks, roughly flat from $75.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for ZYME hit a ceiling of $76.4 million in Q2 2024 and a floor of $51.6 million in Q4 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $68.7 million across 5 years, with a median of $68.5 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 28.69% in 2022 and later decreased 1.38% in 2025.
  • Tracing ZYME's Shares Outstanding (Weighted Average) over 5 years: stood at $51.6 million in 2021, then rose by 26.46% to $65.2 million in 2022, then grew by 5.63% to $68.9 million in 2023, then increased by 10.14% to $75.8 million in 2024, then dropped by 0.58% to $75.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ZYME at $75.4 million in Q4 2025, $75.4 million in Q3 2025, and $75.3 million in Q2 2025.